Bulevirtide: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
== Bulevirtide == | |||
[[File:Bulevirtide.svg|thumb|right|Chemical structure of Bulevirtide]] | |||
'''Bulevirtide''' is an [[antiviral drug]] used in the treatment of chronic [[hepatitis D]] virus (HDV) infection. It is a first-in-class entry inhibitor that targets the [[sodium taurocholate co-transporting polypeptide]] (NTCP), which is a receptor for both [[hepatitis B]] and hepatitis D viruses on the surface of [[hepatocytes]]. | |||
== | == Mechanism of Action == | ||
==Side Effects== | Bulevirtide works by binding to the NTCP receptor on hepatocytes, thereby preventing the entry of HDV into the cells. This inhibition of viral entry reduces the replication of the virus and helps to control the infection. By blocking the entry of the virus, bulevirtide effectively reduces the viral load in patients with chronic hepatitis D. | ||
== Clinical Use == | |||
Bulevirtide is indicated for the treatment of chronic hepatitis D in patients with compensated liver disease. It is administered as a subcutaneous injection, typically once daily. The use of bulevirtide has been shown to improve liver function and reduce the levels of HDV RNA in the blood. | |||
== Side Effects == | |||
Common side effects of bulevirtide include injection site reactions, such as redness and swelling, as well as fatigue and headache. More serious side effects are rare but can include liver enzyme elevations, which require monitoring during treatment. | |||
== Development and Approval == | |||
Bulevirtide was developed as a novel therapeutic option for patients with chronic hepatitis D, a condition for which there were limited treatment options. It received conditional approval from the European Medicines Agency (EMA) in 2020, marking a significant advancement in the management of hepatitis D. | |||
== Related Pages == | |||
* [[Hepatitis D]] | * [[Hepatitis D]] | ||
* [[Hepatitis B]] | * [[Hepatitis B]] | ||
* [[ | * [[Antiviral drug]] | ||
* [[ | * [[Liver disease]] | ||
[[Category: | [[Category:Antiviral drugs]] | ||
[[Category: | [[Category:Hepatitis treatments]] | ||
Latest revision as of 03:35, 13 February 2025
Bulevirtide[edit]
Bulevirtide is an antiviral drug used in the treatment of chronic hepatitis D virus (HDV) infection. It is a first-in-class entry inhibitor that targets the sodium taurocholate co-transporting polypeptide (NTCP), which is a receptor for both hepatitis B and hepatitis D viruses on the surface of hepatocytes.
Mechanism of Action[edit]
Bulevirtide works by binding to the NTCP receptor on hepatocytes, thereby preventing the entry of HDV into the cells. This inhibition of viral entry reduces the replication of the virus and helps to control the infection. By blocking the entry of the virus, bulevirtide effectively reduces the viral load in patients with chronic hepatitis D.
Clinical Use[edit]
Bulevirtide is indicated for the treatment of chronic hepatitis D in patients with compensated liver disease. It is administered as a subcutaneous injection, typically once daily. The use of bulevirtide has been shown to improve liver function and reduce the levels of HDV RNA in the blood.
Side Effects[edit]
Common side effects of bulevirtide include injection site reactions, such as redness and swelling, as well as fatigue and headache. More serious side effects are rare but can include liver enzyme elevations, which require monitoring during treatment.
Development and Approval[edit]
Bulevirtide was developed as a novel therapeutic option for patients with chronic hepatitis D, a condition for which there were limited treatment options. It received conditional approval from the European Medicines Agency (EMA) in 2020, marking a significant advancement in the management of hepatitis D.
